Health and Healthcare
Cramer Speculates on Dialysis Drug (AMAG, XCR)
Published:
Last Updated:
On tonight’s MAD MONEY on CNBC, Jim Cramer said he had a speculative biotech stock. His pick in the sector is AMAG Pharmaceuticals, Inc. (AMAG) because of its soon to be approved ferumoxytol, a newer and better intravenous iron treatment for kidney disease patients on dialysis. Cramer thinks there are many reasons to like this one:
We recently covered a speculative portable dialysis device maker (in prototype and development stage) on our "10 Stocks Under $10" called Xcorporeal, Inc. (AMEX: XCR) which has risen in the last two weeks since being included. We have also reviewed some of the lower-tier dialysis names for this as well.
We would note that this AMAG traded at $56.00 after an upgrade just in early February and shares closed under $40.00 Friday.
Jon C. Ogg
March 28, 2008
Jon Ogg produces the Special Situation Investing Newsletter and he can be reached at [email protected]; he does not own securities in the companies he covers.
The thought of burdening your family with a financial disaster is most Americans’ nightmare. However, recent studies show that over 100 million Americans still don’t have proper life insurance in the event they pass away.
Life insurance can bring peace of mind – ensuring your loved ones are safeguarded against unforeseen expenses and debts. With premiums often lower than expected and a variety of plans tailored to different life stages and health conditions, securing a policy is more accessible than ever.
A quick, no-obligation quote can provide valuable insight into what’s available and what might best suit your family’s needs. Life insurance is a simple step you can take today to help secure peace of mind for your loved ones tomorrow.
Click here to learn how to get a quote in just a few minutes.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.